{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:03:54Z","timestamp":1772017434553,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100011746","name":"NOVARTIS Foundation (Japan) for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s12325-022-02052-1","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T03:02:53Z","timestamp":1643857373000},"page":"1403-1416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9350-6809","authenticated-orcid":false,"given":"Aki","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Yasukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iichiro","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munenori","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiko","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Okita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Takase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"2052_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","volume":"291","author":"NM Bressler","year":"2004","unstructured":"Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900\u20131.","journal-title":"JAMA"},{"key":"2052_CR2","doi-asserted-by":"crossref","unstructured":"Kawasaki R, Wang JJ, Ji GJ, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology 2008;115:1376\u201381, 1381e1\u20132.","DOI":"10.1016\/j.ophtha.2007.11.015"},{"key":"2052_CR3","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.ophtha.2009.04.017","volume":"116","author":"M Yasuda","year":"2009","unstructured":"Yasuda M, Kiyohara Y, Hata Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population: the Hisayama study. Ophthalmology. 2009;116:2135\u201340.","journal-title":"Ophthalmology"},{"key":"2052_CR4","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u201316.","journal-title":"Lancet Glob Health"},{"key":"2052_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"2052_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"2052_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"2052_CR8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1097\/IAE.0b013e3181d50cbf","volume":"30","author":"M Engelbert","year":"2010","unstructured":"Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified \u201ctreat and extend\u201d dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina. 2010;30:1368\u201375.","journal-title":"Retina"},{"key":"2052_CR9","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","volume":"117","author":"OP Gupta","year":"2010","unstructured":"Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117:2134\u201340.","journal-title":"Ophthalmology"},{"key":"2052_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/IAE.0b013e3181de5609","volume":"31","author":"H Oubraham","year":"2011","unstructured":"Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina. 2011;31:26\u201330.","journal-title":"Retina"},{"key":"2052_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1097\/IAE.0b013e3182831265","volume":"33","author":"N Toalster","year":"2013","unstructured":"Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina. 2013;33:1351\u20138.","journal-title":"Retina"},{"key":"2052_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"2052_CR13","first-page":"371","volume":"4","author":"AS Zigmond","year":"1993","unstructured":"Zigmond AS, Snaith RP, Kitamura T. The Hospital Anxiety and Depression Scale. Arch Psychiatr Diagn Clin Eval. 1993;4:371\u20132.","journal-title":"Arch Psychiatr Diagn Clin Eval"},{"key":"2052_CR14","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1167\/iovs.06-0761","volume":"48","author":"A Augustin","year":"2007","unstructured":"Augustin A, Sahel JA, Bandello F, et al. Anxiety and depression prevalence rates in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;48:1498\u2013503.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2052_CR15","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/bjo.2007.116939","volume":"91","author":"A Lotery","year":"2007","unstructured":"Lotery A, Xu X, Zlatava G, Loftus J. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol. 2007;91:1303\u20137.","journal-title":"Br J Ophthalmol"},{"key":"2052_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3129\/i07-153","volume":"42","author":"A Cruess","year":"2007","unstructured":"Cruess A, Zlateva G, Xu X, Rochon S. Burden of illness of neovascular age-related macular degeneration in Canada. Can J Ophthalmol J. 2007;42:836\u201343.","journal-title":"Can J Ophthalmol J"},{"key":"2052_CR17","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1185\/03007990802214300","volume":"24","author":"JM Ruiz-Moreno","year":"2008","unstructured":"Ruiz-Moreno JM, Coco RM, Garcia-Arumi J, Xu X, Zlateva G. Burden of illness of bilateral neovascular age-related macular degeneration in Spain. Curr Med Res Opin. 2008;24:2103\u201311.","journal-title":"Curr Med Res Opin"},{"key":"2052_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0181-5512(08)70346-2","volume":"31","author":"G Soubrane","year":"2008","unstructured":"Soubrane G, Zlateva G, Xu X, Buggage R, Kosa M. [Humanistic burden and health resource utilization among neovascular age-related macular degeneration patients in France]. J Fr Ophtalmol. 2008;31:138\u201345.","journal-title":"J Fr Ophtalmol"},{"key":"2052_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00347-008-1797-9","volume":"106","author":"D Pauleikhoff","year":"2009","unstructured":"Pauleikhoff D, Scheider A, Wiedmann P, et al. [Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications]. Der Ophthal Zeitschr Deutsc Ophthalmol Gesellsch. 2009;106:242\u201351.","journal-title":"Der Ophthal Zeitschr Deutsc Ophthalmol Gesellsch"},{"key":"2052_CR20","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s11136-017-1547-z","volume":"26","author":"YM Paulus","year":"2017","unstructured":"Paulus YM, Jefferys JL, Hawkins BS, Scott AW. Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes. Qual Life Res. 2017;26:2139\u201351.","journal-title":"Qual Life Res"},{"key":"2052_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ajo.2004.02.011","volume":"138","author":"LM Dong","year":"2004","unstructured":"Dong LM, Childs AL, Mangione CM, et al. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am J Ophthalmol. 2004;138:91\u2013108.","journal-title":"Am J Ophthalmol"},{"key":"2052_CR22","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00417-012-2177-3","volume":"251","author":"KM Droege","year":"2013","unstructured":"Droege KM, Muether PS, Hermann MM, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Archiv Clin Exp Ophthal. 2013;251:1281\u20134.","journal-title":"Graefes Archiv Clin Exp Ophthal"},{"key":"2052_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mones J. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125:57\u201365.","journal-title":"Ophthalmology"},{"key":"2052_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/bjophthalmol-2017-310822","volume":"102","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Ou WC, Croft DE, et al. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2018;102:460\u20134.","journal-title":"Br J Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02052-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02052-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02052-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T09:24:41Z","timestamp":1647077081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02052-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2052"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02052-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"12 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}